These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 32322397)
1. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. Choudhary R; Sharma AK New Microbes New Infect; 2020 May; 35():100684. PubMed ID: 32322397 [TBL] [Abstract][Full Text] [Related]
2. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. Siddiqui AJ; Jahan S; Ashraf SA; Alreshidi M; Ashraf MS; Patel M; Snoussi M; Singh R; Adnan M J Biomol Struct Dyn; 2021 Oct; 39(17):6828-6841. PubMed ID: 32752944 [TBL] [Abstract][Full Text] [Related]
3. Multidrug treatment for COVID-19. Ohe M; Furuya K; Goudarzi H Drug Discov Ther; 2021 Mar; 15(1):39-41. PubMed ID: 33612572 [TBL] [Abstract][Full Text] [Related]
4. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU. Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V; Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163 [TBL] [Abstract][Full Text] [Related]
5. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Derendorf H Int J Antimicrob Agents; 2020 Jun; 55(6):106007. PubMed ID: 32389720 [TBL] [Abstract][Full Text] [Related]
6. Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. Schaffer AL; Henry D; Zoega H; Elliott JH; Pearson SA PLoS One; 2022; 17(6):e0269482. PubMed ID: 35704621 [TBL] [Abstract][Full Text] [Related]
7. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366 [TBL] [Abstract][Full Text] [Related]
8. Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. Albani F; Fusina F; Giovannini A; Ferretti P; Granato A; Prezioso C; Divizia D; Sabaini A; Marri M; Malpetti E; Natalini G J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32872629 [TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Nina PB; Dash AP Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241 [TBL] [Abstract][Full Text] [Related]
11. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019. Tuncer T; Karaci M; Boga A; Durmaz H; Guven S Cardiol Young; 2020 Oct; 30(10):1482-1485. PubMed ID: 32686633 [TBL] [Abstract][Full Text] [Related]
12. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin. Fatima U; Rizvi SSA; Fatima S; Hassan MI J Interferon Cytokine Res; 2020 Oct; 40(10):469-471. PubMed ID: 32881593 [TBL] [Abstract][Full Text] [Related]
13. Chloroquine and COVID-19: Should We Care about Ototoxicity? Monteiro EMR; Nascimento MFL; Brito TRC; Lima MC; Sefair LR; Pedrosa MM Int Arch Otorhinolaryngol; 2020 Jul; 24(3):e359-e363. PubMed ID: 32774508 [No Abstract] [Full Text] [Related]
14. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Jans DA; Wagstaff KM Cells; 2020 Sep; 9(9):. PubMed ID: 32942671 [TBL] [Abstract][Full Text] [Related]
15. Drug safety of frequently used drugs and substances for self-medication in COVID-19. Baracaldo-Santamaría D; Pabón-Londoño S; Rojas-Rodriguez LC Ther Adv Drug Saf; 2022; 13():20420986221094141. PubMed ID: 35493401 [TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update. Pal A; Pawar A; Goswami K; Sharma P; Prasad R Indian J Clin Biochem; 2020 Jul; 35(3):274-284. PubMed ID: 32641874 [TBL] [Abstract][Full Text] [Related]
17. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. Gabriels J; Saleh M; Chang D; Epstein LM HeartRhythm Case Rep; 2020 May; 6(5):241-243. PubMed ID: 32363144 [No Abstract] [Full Text] [Related]
18. An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction. Lee TC; MacKenzie LJ; McDonald EG; Tong SYC Int J Infect Dis; 2020 Sep; 98():216-217. PubMed ID: 32623080 [No Abstract] [Full Text] [Related]
19. Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis? Ramírez C; Herrera-Paz EF; Peralta G; Rodríguez G; Durón RM EClinicalMedicine; 2021 Feb; 32():100744. PubMed ID: 33558858 [No Abstract] [Full Text] [Related]
20. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin. Marzo T; Messori L ACS Med Chem Lett; 2020 Jun; 11(6):1067-1068. PubMed ID: 32547693 [No Abstract] [Full Text] [Related] [Next] [New Search]